Search the Newsreel

ATI (ATI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Board Chair, President and Chief Executive Officer - Kimberly FieldsSenior Vice President and Chief Financial Officer - James FosterVice President of Investor Relations - Rob Rengel TAKEAWAYS Revenue …

Leggett & Platt Inc. stock underperforms Thursday when compared to competitors despite daily gains

Shares of Leggett & Platt Inc. (LEG) rose 2.97% to $9.70 on Thursday, amidst a positive trading session for the broader market. Despite this gain, the stock underperformed its competitors. Leggett & Platt Inc. closed 25.38% below its 52-week high of $13.00.

Legence revenue rises 110.7% to $1.26 billion

Resilient Allegion stock holds above $166 as investors digest stake reduction news

Allegion plc (IE00BFRT3W74) stock has remained above $166 after an institutional shareholder reduced its position, with the stock closing at $166.06 on August 12, 2026, and showing a modest positive move to $167.77 in extended trading. This stability suggests that investors are focusing on …

Collegium Pharmaceutical to repurchase $50 million in stock By Investing.com

Collegium Pharmaceutical has entered into an Accelerated Share Repurchase agreement with Jefferies LLC to buy back $50 million of its common stock, part of a larger $150 million share repurchase program. The company will receive an initial delivery of 1,556,420 shares, representing about 80% …

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Ian Karp President and Chief Executive Officer - Vikram Karnani Chief Financial Officer - Colleen Tupper Full Conference Call Transcript Operator: Greetings, and …

Legence Q2 Loss Widens On Impairment Charges; Raises FY26 Outlook

(RTTNews) - Legence Corp. (LGN), a provider of energy efficiency, engineering and sustainable infrastructure solutions, on Thursday reported a wider second-quarter loss, despite strong revenue growth, primarily due to goodwill and asset impairment charges. Net loss attributable to Legence widened to $27.84 million or …

Collegium gains on accelerated share buybacks (COLL:NASDAQ)

Collegium Pharmaceutical (COLL) saw its stock rise in premarket trading after announcing an accelerated share repurchase agreement with Jefferies (JEF) to buy back $50 million of its company stock. This accelerated buyback is part of a larger $150 million share repurchase program authorized by …

Mesa Gateway's biggest airline added 34 new flights. Where you can fly

Mesa Gateway Airport experienced record passenger numbers in the 2025-26 fiscal year despite service reductions, showcasing its resilience. Allegiant Air, the airport's primary carrier, is restoring service with 34 additional roundtrip flights for the upcoming holiday season. These added flights are capacity increases on …

Collegium Pharmaceutical launches $50M accelerated share repurchase under $150M buyback program

Collegium Pharmaceutical has initiated a $50 million accelerated share repurchase (ASR) program with Jefferies, receiving an initial 1,556,420 shares. This ASR is part of a larger $150 million board-authorized buyback program, with the final share count to be determined by the volume-weighted average price …

Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. announced an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This ASR is part of a larger $150 million share repurchase program, leaving $100 million remaining after this transaction. The company believes its …

JPMorgan Chase & Co. Cuts Legal & General Group (LON:LGEN) Price Target to GBX 270

Allegro Microsystems started with Buy rating at Benchmark (ALGM:NASDAQ)

Benchmark initiated coverage on Allegro Microsystems (ALGM) with a Buy rating and a $60 price target, anticipating future growth driven by the automotive sector. Shares of ALGM saw a 1.9% increase in premarket trading following the news. The investment firm believes Allegro Microsystems is …

Diversified Management Inc. Reduces Stake in Allegion PLC $ALLE

Diversified Management Inc. significantly reduced its holdings in Allegion PLC (NYSE:ALLE) by 87.5% in the second quarter, selling over 14,000 shares. Despite this, institutional investors still hold a substantial 92.21% of the company's stock. Allegion PLC exceeded its quarterly earnings and revenue expectations, and …

Assenagon Asset Management S.A. Has $5.41 Million Stock Holdings in Allegiant Travel Company $ALGT

Assenagon Asset Management S.A. significantly reduced its stake in Allegiant Travel Company (NASDAQ:ALGT) by 68.4% in the second quarter, now holding 45,982 shares valued at $5.41 million. Despite this reduction, Allegiant Travel reported strong second-quarter EPS of $2.19, surpassing analyst expectations, and maintains a …

Legend Holdings flags Lenovo Q1 profit hit despite strong revenue growth

LegalZoom (LZ) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Madeline Crane Chairman and Chief Executive Officer - Jeffrey Stibel Chief Operating Officer and Chief Financial Officer - Noel Watson Full Conference Call …

Erin Hagen Sells 2,285 Shares of Allegro MicroSystems (NASDAQ:ALGM) Stock

Erin Hagen, SVP of Allegro MicroSystems (NASDAQ:ALGM), sold 2,285 shares of the company's stock for $101,431.15, reducing her direct holdings by 6.85%. This transaction comes as Allegro MicroSystems reported strong quarterly earnings, beating estimates with $0.23 EPS and a 27.5% year-over-year revenue increase. The …

Allegiant Travel Enters Oversold Territory (ALGT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength …

Legend Biotech Shares Fall After Oppenheimer Downgrade

Legend Biotech's shares experienced a decline following an Oppenheimer downgrade from Outperform to Perform, citing potential pressures from competition and a CEO transition. Despite this, RBC maintained an Outperform rating for Legend Biotech, adjusting its price target slightly, due to positive outlooks on Carvykti …

Leggett & Platt Inc. stock outperforms competitors despite losses on the day

Leggett & Platt Inc. (LEG) stock experienced a 1.15% decline, closing at $9.42 on Wednesday. Despite this loss, the stock's performance outpaced the broader market, which saw the S&P 500 Index rise by 0.26% and the Dow Jones Industrial Average fall by 0.04%. Leggett …

Allegion PLC stock outperforms competitors despite losses on the day

Allegion PLC's stock (ALLE) fell 1.38% to $166.11 on Wednesday, despite a mixed trading session where the S&P 500 rose and the Dow Jones Industrial Average slightly declined. The stock is currently 9.28% below its 52-week high of $183.11, reached in February.

3 Reasons Why ATI (ATI) Is a Great Growth Stock

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task. By their very …

Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade

LEGN Downgraded by Oppenheimer -- Price Target Lowered to $40.00

ATI Maintained by Keybanc -- Price Target Raised to $258

Keybanc analyst Samuel McKinney has maintained an Overweight rating for ATI Inc (ATI) and increased its price target from $211 to $258, reflecting a positive outlook driven by strong demand in key markets. Despite the positive analyst sentiment, GuruFocus indicates ATI is significantly overvalued, …

Legend Biotech stock downgraded at Oppenheimer (LEGN:NASDAQ)

Oppenheimer downgraded Legend Biotech (LEGN) to Perform from Outperform following the resignation of its CEO, competitive pressures, and reduced M&A prospects. The analyst cited these factors as reasons for the downgrade. Legend Biotech's shares saw a decline on Wednesday after the announcement.

5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

Collegium Pharmaceutical's Q2 earnings showed sales growth driven by its ADHD business, with Jornay PM revenue up 41% year-over-year, but overall revenue missed Wall Street estimates due to pricing pressure on the NUCYNTA pain franchise. Despite this, the company raised its full-year revenue guidance. …

KeyBanc raises ATI stock price target to $258 on margin strength

KeyBanc has increased its price target for ATI Inc. (NYSE:ATI) to $258 from $211, maintaining an Overweight rating, following the company's strong second-quarter 2026 results. The adjustment reflects continued margin strength and growth in the aerospace and defense sectors, along with ATI's niche higher-margin …

Oppenheimer downgrades Legend Biotech stock rating on M&A concerns

Oppenheimer downgraded Legend Biotech (NASDAQ:LEGN) to Perform from Outperform, lowering its price target to $40 due to diminished M&A prospects, particularly after Johnson & Johnson was removed as a potential buyer. The firm also cited concerns over the CEO's departure, financing issues, and weak …

Tema ETFs LLC Sells 9,216 Shares of ATI Inc. $ATI

Tema ETFs LLC reduced its stake in ATI Inc. by 11.3% in the second quarter, selling 9,216 shares but retaining a significant holding. Despite this sale, other institutional investors increased their positions, and analysts maintain a positive outlook with a consensus "Buy" rating and …

RBC Adjusts Price Target on Legend Biotech to $58 From $59, Maintains Outperform Rating

RBC Capital Markets has adjusted its price target for Legend Biotech (LEGN) to $58, down from $59, while reiterating an Outperform rating on the stock. This revision comes amidst recent news for Legend Biotech, including a downgrade from Oppenheimer and the company reporting its …

Legion Consortium Signals Interim Profit on Logistics Demand Rebound

Legend Biotech Releases Q2 2026 Financial Results

Legend Biotech (LEGN) reported strong Q2 2026 financial results, with adjusted earnings of $0.16 per share, surpassing estimates. The company generated $387.5 million in revenue, largely driven by its CARVYKTI collaboration, indicating significant growth and market penetration for its cell therapy platform. Wall Street …

Legend Turns Profitable In Q2 As CARVYKTI Sales Jump By 50%

(RTTNews) - Legend Biotech Corporation (LEGN) released financial results for the second quarter ended June 30, 2026. The commercial-stage company turned profitable in the second quarter, compared with a loss in the prior-year quarter, driven by higher collaboration revenue and improved operating income. For …

Legend Biotech (LEGN) Stock Rebounds As Profit Arrives But Carvykti Risk Persists